Journal Mobile Options
Table of Contents
Vol. 60, No. 1, 2009
Issue release date: September 2009
Neuropsychobiology 2009;60:31–36

Dysbindin and D-Amino-Acid-Oxidase Gene Polymorphisms Associated with Positive and Negative Symptoms in Schizophrenia

Wirgenes K.V. · Djurovic S. · Agartz I. · Jönsson E.G. · Werge T. · Melle I. · Andreassen O.A.
aInstitute of Psychiatry, University of Oslo, Departments of bMedical Genetics and cPsychiatry, Oslo University Hospital – Ulleval, and dDepartment of Psychiatric Research, Diakonhjemmet Hospital, Oslo, Norway; eDepartment of Clinical Neuroscience, HUBIN Project, Psychiatry Section, Karolinska Institutet and Hospital, Stockholm, Sweden; fResearch Institute of Biological Psychiatry, H:S Sct. Hans Hospital, Roskilde, Denmark

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: Schizophrenia is a genetically complex disorder with an unknown pathophysiology. Several genes implicated in glutamate metabolism have been associated with the disorder. Recent studies of polymorphisms in the dystrobrevin-binding protein 1 gene (DTNBP1; dysbindin) and D-amino-acid-oxidase (DAO) gene, both involved in glutamate receptor function, reported associations with negative symptoms and with anxiety and depression, respectively, when measured with the Positive and Negative Syndrome Scale (PANSS). Methods: In the present study, the suggested association between dysbindin and DAO single nucleotide polymorphisms (SNPs) and PANSS scores was analyzed in 155 Norwegian schizophrenia patients. Results: There was a significant association between the dysbindin SNP rs3213207 and severity of both negative symptoms and total symptom load, as well as between the DAO SNP rs2070587 and total symptom score and severity of anxiety and depression. Conclusion: The present association of dysbindin SNPs with negative symptoms and DAO SNPs with anxiety and depression is a replication of earlier findings and strengthens the hypothesis of a genetic association. It further indicates involvement of glutamate abnormalities in schizophrenia pathophysiology, as suggested by previous studies, and suggests that polymorphisms may be associated with subgroups of clinical characteristics in schizophrenia.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Mueser KT, McGurk SR: Schizophrenia. Lancet 2004;363:2063–2072.
  2. Craddock N, Owen MJ: The beginning of the end for the Kraepelinian dichotomy. Br J Psychiatry 2005;186:364–366.
  3. Fanous AH, Kendler KS: Genetic heterogeneity, modifier genes, and quantitative phenotypes in psychiatric illness: searching for a framework. Mol Psychiatry 2005;10:6–13.
  4. Harrison PJ, Weinberger DR: Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 2005;10:40–68.
  5. Norton N, Williams HJ, Owen MJ: An update on the genetics of schizophrenia. Curr Opin Psychiatry 2006;19:158–164.
  6. Chumakov I, Blumenfeld M, Guerassimenko O, Cavarec L, Palicio M, Abderrahim H, Bougueleret L, Barry C, Tanaka H, La RP, Puech A, Tahri N, Cohen-Akenine A, Delabrosse S, Lissarrague S, Picard FP, Maurice K, Essioux L, Millasseau P, Grel P, Debailleul V, Simon AM, Caterina D, Dufaure I, Malekzadeh K, et al: Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc Natl Acad Sci USA 2002;99:13675–13680.
  7. Lang UE, Puls I, Muller DJ, Strutz-Seebohm N, Gallinat J: Molecular mechanisms of schizophrenia. Cell Physiol Biochem 2007;20:687–702.
  8. Coyle JT: Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 2006;26:365–384.
  9. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS: Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994;51:199–214.
  10. Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA: Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 2001;25:455–467.
  11. Gao XM, Sakai K, Roberts RC, Conley RR, Dean B, Tamminga CA: Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. Am J Psychiatry 2000;157:1141–1149.
  12. Ibrahim HM, Hogg AJ Jr, Healy DJ, Haroutunian V, Davis KL, Meador-Woodruff JH: Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia. Am J Psychiatry 2000;157:1811–1823.
  13. Meador-Woodruff JH, Healy DJ: Glutamate receptor expression in schizophrenic brain. Brain Res Brain Res Rev 2000;31:288–294.
  14. Laruelle M, Frankle WG, Narendran R, Kegeles LS, Abi-Dargham A: Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation. Clin Ther 2005;27(suppl A):S16–S24.
  15. Lindsley CW, Shipe WD, Wolkenberg SE, Theberge CR, Williams DL Jr, Sur C, Kinney GG: Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia. Curr Top Med Chem 2006;6:771–785.
  16. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, Mosolov SN, Neznanov NG, Reznik AM, Smulevich AB, Tochilov VA, Johnson BG, Monn JA, Schoepp DD: Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat Med 2007;13:1102–1107.
  17. Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261–276.
  18. Corvin A, Donohoe G, Nangle JM, Schwaiger S, Morris D, Gill M: A dysbindin risk haplotype associated with less severe manic-type symptoms in psychosis. Neurosci Lett 2008;431:146–149.
  19. DeRosse P, Funke B, Burdick KE, Lencz T, Ekholm JM, Kane JM, Kucherlapati R, Malhotra AK: Dysbindin genotype and negative symptoms in schizophrenia. Am J Psychiatry 2006;163:532–534.
  20. Fanous AH, van den Oord EJ, Riley BP, Aggen SH, Neale MC, O’Neill FA, Walsh D, Kendler KS: Relationship between a high-risk haplotype in the DTNBP1 (dysbindin) gene and clinical features of schizophrenia. Am J Psychiatry 2005;162:1824–1832.
  21. Corvin A, Donohoe G, McGhee K, Murphy K, Kenny N, Schwaiger S, Nangle JM, Morris D, Gill M: D-amino acid oxidase (DAO) genotype and mood symptomatology in schizophrenia. Neurosci Lett 2007;426:97–100.
  22. Hansen T, Olsen L, Lindow M, Jakobsen KD, Ullum H, Jonsson E, Andreassen OA, Djurovic S, Melle I, Agartz I, Hall H, Timm S, Wang AG, Werge T: Brain expressed microRNAs implicated in schizophrenia etiology. PLoS ONE 2007;2:e873.
  23. Spitzer RL, Williams JB, Gibbon M, First MB: The Structured Clinical Interview for DSM-III-R (SCID). I. History, rationale, and description. Arch Gen Psychiatry 1992;49:624–629.
  24. Ventura J, Liberman RP, Green MF, Shaner A, Mintz J: Training and quality assurance with the Structured Clinical Interview for DSM-IV (SCID-I/P). Psychiatry Res 1998;79:163–173.
  25. Emsley R, Rabinowitz J, Torreman M: The factor structure for the Positive and Negative Syndrome Scale (PANSS) in recent-onset psychosis. Schizophr Res 2003;61:47–57.
  26. Liu X, He G, Wang X, Chen Q, Qian X, Lin W, Li D, Gu N, Feng G, He L: Association of DAAO with schizophrenia in the Chinese population. Neurosci Lett 2004;369:228–233.
  27. Wigginton JE, Abecasis GR: PEDSTATS: descriptive statistics, graphics and quality assessment for gene mapping data. Bioinformatics 2005;21:3445–3447.
  28. Straub RE, Jiang Y, MacLean CJ, Ma Y, Webb BT, Myakishev MV, Harris-Kerr C, Wormley B, Sadek H, Kadambi B, Cesare AJ, Gibberman A, Wang X, O’Neill FA, Walsh D, Kendler KS: Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Am J Hum Genet 2002;71:337–348.
  29. Benson MA, Sillitoe RV, Blake DJ: Schizophrenia genetics: dysbindin under the microscope. Trends Neurosci 2004;27:516–519.
  30. Williams NM, O’Donovan MC, Owen MJ: Is the dysbindin gene (DTNBP1) a susceptibility gene for schizophrenia? Schizophr Bull 2005;31:800–805.
  31. Schwab SG, Knapp M, Mondabon S, Hallmayer J, Borrmann-Hassenbach M, Albus M, Lerer B, Rietschel M, Trixler M, Maier W, Wildenauer DB: Support for association of schizophrenia with genetic variation in the 6p22.3 gene, dysbindin, in sib-pair families with linkage and in an additional sample of triad families. Am J Hum Genet 2003;72:185–190.
  32. Funke B, Finn CT, Plocik AM, Lake S, DeRosse P, Kane JM, Kucherlapati R, Malhotra AK: Association of the DTNBP1 locus with schizophrenia in a US population. Am J Hum Genet 2004;75:891–898.
  33. Bellon A: New genes associated with schizophrenia in neurite formation: a review of cell culture experiments. Mol Psychiatry 2007;12:620–629.
  34. Chanock SJ, Manolio T, Boehnke M, et al: Replicating genotype-phenotype associations. Nature 2007;447:655–660.
  35. Raybould R, Green EK, MacGregor S, Gordon-Smith K, Heron J, Hyde S, Caesar S, Nikolov I, Williams N, Jones L, O’Donovan MC, Owen MJ, Jones I, Kirov G, Craddock N: Bipolar disorder and polymorphisms in the dysbindin gene (DTNBP1). Biol Psychiatry 2005;57:696–701.
  36. Prata D, Breen G, Osborne S, Munro J, St Clair D, Collier D: Association of DAO and G72(DAOA)/G30 genes with bipolar affective disorder. Am J Med Genet B Neuropsychiatr Genet 2008;147B:914–197.
  37. Fallin MD, Lasseter VK, Avramopoulos D, Nicodemus KK, Wolyniec PS, McGrath JA, Steel G, Nestadt G, Liang KY, Huganir RL, Valle D, Pulver AE: Bipolar I disorder and schizophrenia: a 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios. Am J Hum Genet 2005;77:918–936.
  38. Liu YL, Fann CS, Liu CM, Chang CC, Wu JY, Hung SI, Liu SK, Hsieh MH, Hwang TJ, Chan HY, Chen JJ, Faraone SV, Tsuang MT, Chen WJ, Hwu HG: No association of G72 and D-amino acid oxidase genes with schizophrenia. Schizophr Res 2006;87:15–20.
  39. Schumacher J, Jamra RA, Freudenberg J, Becker T, Ohlraun S, Otte AC, Tullius M, Kovalenko S, Bogaert AV, Maier W, Rietschel M, Propping P, Nothen MM, Cichon S: Examination of G72 and D-amino-acid oxidase as genetic risk factors for schizophrenia and bipolar affective disorder. Mol Psychiatry 2004;9:203–207.
  40. Wood LS, Pickering EH, Dechairo BM: Significant support for DAO as a schizophrenia susceptibility locus: examination of five genes putatively associated with schizophrenia. Biol Psychiatry 2007;61:1195–1199.
  41. Yamada K, Ohnishi T, Hashimoto K, Ohba H, Iwayama-Shigeno Y, Toyoshima M, Okuno A, Takao H, Toyota T, Minabe Y, Nakamura K, Shimizu E, Itokawa M, Mori N, Iyo M, Yoshikawa T: Identification of multiple serine racemase (SRR) mRNA isoforms and genetic analyses of SRR and DAO in schizophrenia and D-serine levels. Biol Psychiatry 2005;57:1493–1503.
  42. Madeira C, Freitas ME, Vargas-Lopes C, Wolosker H, Panizzutti R: Increased brain D-amino acid oxidase (DAAO) activity in schizophrenia. Schizophr Res 2008;101:76–83.
  43. Sanacora G, Zarate CA, Krystal JH, Manji HK: Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 2008;7:426–437.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50